https://www.live-feeds.com/feed/fda-advisors-unanimously-vote-to-approve-moderna-s-mrna-after-agency-dramaContinuously updated, source-cited coverage. https://www.live-feeds.com/feed/fda-advisors-unanimously-vote-to-approve-moderna-s-mrna-after-agency-dramahttps://www.live-feeds.com/feed/fda-advisors-unanimously-vote-to-approve-moderna-s-mrna-after-agency-drama#u18773Tue, 30 Jun 2026 11:46:37 +0000FDA advisers voted 9-0 on June 18 to recommend the approval of Moderna's mRNA-based flu vaccine, mFlusiva, for adults 50 and older. Phase 3 data indicated the shot is about 27% more effective than standard flu vaccines. The FDA is expected to issue a final decision by August 5.What's confirmed:The FDA Vaccines and Related Biological Products Advisory Committee voted 9-0 on June 18, 2026, to endorse mFlusiva.The vaccine is intended for adults 50 and older.Phase 3 data showed mFlusiva to be about 27% more effective than a standard flu vaccine.A final FDA decision is expected by August 5.Sti https://www.live-feeds.com/feed/fda-advisors-unanimously-vote-to-approve-moderna-s-mrna-after-agency-dramahttps://www.live-feeds.com/feed/fda-advisors-unanimously-vote-to-approve-moderna-s-mrna-after-agency-drama#u13365Thu, 25 Jun 2026 21:56:12 +0000The FDA Vaccines and Related Biological Products Advisory Committee voted 9-0 on June 18, 2026, to endorse Moderna's mFlusiva. The panel found that the benefits of the vaccine outweigh its risks for adults 50 and older. A final FDA decision is expected by August 5.What's confirmed:The FDA Vaccines and Related Biological Products Advisory Committee voted 9-0 to endorse Moderna's mRNA-1010 influenza vaccine, also known as mFlusiva.The panel voted on June 18, 2026, that the benefits of the vaccine outweigh its risks.The vaccine is intended for adults 50 and older, with standard approval https://www.live-feeds.com/feed/fda-advisors-unanimously-vote-to-approve-moderna-s-mrna-after-agency-dramahttps://www.live-feeds.com/feed/fda-advisors-unanimously-vote-to-approve-moderna-s-mrna-after-agency-drama#u9000Tue, 23 Jun 2026 00:05:36 +0000An FDA advisory committee voted 9-0 to recommend the approval of Moderna's mRNA-1010 influenza vaccine. The agency is expected to issue a final verdict by Aug. 5. This follows a brief period in February where the FDA refused to review the vaccine due to trial inadequacies.What's confirmed:An FDA advisory panel voted 9-0 to recommend the approval of Moderna's mRNA-1010 vaccine.The FDA is expected to reach a verdict by Aug. 5.Still unconfirmed:The FDA briefly refused to review the vaccine in February citing trial inadequacies before reversing course. https://www.live-feeds.com/feed/fda-advisors-unanimously-vote-to-approve-moderna-s-mrna-after-agency-dramahttps://www.live-feeds.com/feed/fda-advisors-unanimously-vote-to-approve-moderna-s-mrna-after-agency-drama#u6841Sun, 21 Jun 2026 03:25:46 +0000Federal health advisers recommended the approval of Moderna's mRNA-1010 influenza vaccine. The shot targets adults aged 50 and older. It utilizes the same mRNA technology used during the pandemic.What's confirmed:An FDA advisory committee voted 9-0 to recommend Moderna's mRNA-1010 influenza vaccine for adults aged 50 and older.The vaccine uses mRNA technology. https://www.live-feeds.com/feed/fda-advisors-unanimously-vote-to-approve-moderna-s-mrna-after-agency-dramahttps://www.live-feeds.com/feed/fda-advisors-unanimously-vote-to-approve-moderna-s-mrna-after-agency-drama#u5069Fri, 19 Jun 2026 21:31:23 +0000An FDA advisory committee voted 9-0 to recommend Moderna's mRNA-1010 influenza vaccine for adults aged 50 and older. The decision follows a period of agency controversy. A final approval decision is expected by August 5.What's confirmed:FDA advisors voted unanimously to recommend Moderna's mRNA influenza vaccine for adults 50 and older.The advisory panel's vote was 9-0.The investigational vaccine is identified as mRNA-1010.An FDA approval decision is pending for August 5.Still unconfirmed:Moderna's mRNA flu vaccine expands B cell response breadth in humans.MRNA stock had it